Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results
Go back to Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results| (NASDAQ: BPMC) | Delayed: 129.46 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $129.46 | 52 Week High | $35.96 | |||
| Open | $129.46 | 52 Week Low | $13.04 | |||
| Day High | $129.46 | P/E | N/A | |||
| Day Low | $129.46 | EPS | $0.00 | |||
| Volume | 9,621 | |||||
